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SummAry
A nine year aged male presented with facial lesions and the problem of responding to 
conventional treatment of leishmaniasis. multiple injections of antimony and several 
topical ointments had been administered in hospital but fresh lesions erupted with 
potential to disfigure. Smears examined from nodular lesions confirmed presence of 
leishmania amastigotes and parenteral pentostam was commenced for over eight 
weeks. A partial clinical outcome was achieved judged by extent of re-epithelialisation. 
combined therapy of pentostam and oral allopurinol at a dose of 7mg/kg/ day was 
started and finalised at 120 days. All facial lesions receded and 100% re-epithelialisation 
of the lesions established.
IntroductIon
Approximately 1.5 million new cases of cutaneous 
leishmaniasis (CL) are considered to occur annually (1). 
Old World CL is endemic in the Middle East, northern, 
and sub-saharan Africa; the Mediterranean basin; and 
parts of Indian subcontinent and northwestern China 
(2). CL is being encountered more frequently in Europe 
and North America because of increasing travel and 
immigration from endemic areas but the primary 
unmet need is finding a rapidly, easily-administered, 
inexpensive, less toxic, effective species-specific treatment 
(3). It is argued that the most extensive investigations 
of treatment of New World CL have been performed 
against L. panamensis disease in Colombia (4). The oral 
antifungal ketaconazole can be effective for the more 
rapidly self-curing forms of disease (cutaneous disease 
caused by L. mexicana and L. panamensis from Central 
America) and a short course of antimony may be effective 
against L. braziliensis in Guatemala (5). Its noteworth that 
the causative species of CL determines the treatments (6). 
For example, paromomycin ointments are effective in L. 
major, L. tropica, L. mexirona, and L. panamensis infections. 
In L. braziliensis localised leishmaniasis, both paromomycin 
and imiquimod may be topically applied.
 Both oral fluconazole and zinc sulfate are useful 
in L. major (7). The literature findings indicate that 
itraconazole given at prolonged period, may be a 
valid option for the treatment of CL, mainly in those 
cases unresponsive to conventional drugs (Consigli 
(8). Miltefosine, which is very effective in VL caused 
by L. donovani, appears ineffective in L. major and L. 
braziliensis infections. Intramuscular pentamidine 
is required for L. guyanensis CL, for which systemic 
antimony is not effective. Ambisome® rould be an 
alternative to antimony in South American CL with 
mucosal involvement (especially L. braziliensis and 
L. guyanensis). Tested efficacy of thermotherapy or 
cryotherapy to treat CL and sodium stibogluconate 
administered intralesionally have shown varied 
results elsewhere (9-11).
 Treatment for CL has not been standardised 
in Kenya to date. The first-line treatment involves 
administering pentostam or glucantirne which require 
multiple injections, are expensive, and can cause 
reversible electrocardiogram alterations. Hence, WHO 
recommendation no treatment for uncomplicated CL. 
The exception to this recommendation would be in 
most NWCL, where systemic treatment is indicated 
because of the risk of mucosal spread. Compliance 
with this recommendation is also poor, as caring 
practitioners and their patients being anxious, know 




that untreated lesions may take several months to 
heal especially those due to L. tropica, and leave 
undesirable scars. The parasitologic confirmation 
of CL by microscopy or species-specific diagnosis 
using polymerase chain reaction, is obligatory before 
chemotherapy can be considered. Accordingly, the 
biochemical basis for effectiveness of antimonials 
is unknown but may involve inhibition of ATP 
synthesis (12). Care should be maximised in children 
with underlying cardiac disease and with low 
serum potassium (13). Oral allopurinol is usually 
well tolerated, the most common side effect being 
rashes, sometimes fever. A rare but serious adverse 
event being allopurinol hypersensitivity syndrome. 
Available drug information indicate that allopurinol 
is not active but undergoes hepatic conversion (about 
60-70% of allopurinol) to its active metabolites, 
oxipurinol and allopurinol riboside. It is the riboside 
received by patients given concurrently or without 
probenecid, which is known to show antileishmanial 
effect in several clinical studies (14,15). Its suggested 
care should be appropriate in patients with renal 
disease due to net absorption of oxipurinol (16). 
Previous studies in vitro have shown synergism 
between allopurinol and pentavalent antimony in 
tissue-culture systems and elsewhere randomised 
controlled trials in humans in Colombia support 
the view of synergism (17). The simple rationale of 
combining allopurinol and pentostam was derived 
from the fact it had been successively used as an 
adjuvant within the CCR setting in the treatment of 
those trial cases of VL that did not achieve clinical 
and parasitological cure with brand pentostam alone 
at recommended duration of 30 days.
cASe repOrT
A nine year aged male from Muruku village, 
Salama location, Laikipia west was referred to the 
CCR with fulminating facial lesions. The boy had 
inflamed papulonodular and fungated lesions spread 
over the face. A previous histological report was 
available of facial biopsy removed from the boy at 
the Nakuru general hospital in December 2005. The 
report indicated the lesions were cystic epidermoid 
lesions. A parasitological re-examination of the 
stored specimen in the same hospital in December 
2006, confirmed presence of Leishmania amastigotes. 
During the one year period, varied treatment options 
were used including, brand sodium stibogluconate 
(Pentostam®) injections given for 52 days and topical 
ointments such as ketoconazole. While on treatment, 
the patient continued to experience fresh facial lesions 
which erupted with potential to disfigure. Hence, the 
patient was referred to the CCR where an informed 
consent was obtained for skin slit sample collection 
for study. Microscopy examination of Giemsa stained 
skin slit material from selected nodular lesions on 
the face were positive for Leishmania amastigotes and 
graded 4+ using methodology described by Bryceson 
and Chulay (18).
 Parenteral pentostam was started at a dose of 
20mg/kg once daily for 60 days on outpatient basis. 
A partial clinical outcome was achieved with no new 
lesions observed on assessment as the definition of 
lesion cure and failure were based on both clinical and 
parasitological criteria. Complete clinical response 
was defined as 100% re-epithelialisation of lesions. 
A combined therapy of pentostam at similar dose 
and oral allopurinol at a dose of 7mg/kg/ day was 
started and finalised after 120 days. No adverse events 
were reported while the patient was on treatment. 
Facial lesions receded and 100% epithelialisation 
of lesions established. Healing left a thin smooth 
scarring with reversed hypopigmentation. While it 
was possible to conclude that a clinical cure had been 
achieved, a parasitological assessment could not be 
done on a completely healed scar. A series of medical 
photography as evidence was created to document 
the visual changes on the patient before, during and 
after the treatment period (fig 1, 2, 3) 
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diScuSSiOn
In primary care most CL cases are often mistaken 
for other common dermatological disorders such 
as fungal infections, bacterial, eczema, or chronic 
ulcers that leads to a delay in appropriate treatment. 
In some places patients consulted from one to 
seven physicians before CL was diagnosed (19). 
This can also lead to delay in the correct diagnosis 
and inadvertent exposure to adverse events of 
inappropriate treatment. Overall, the median time 
from noticing of lesions to the release of drugs can 
be unexpectedly prolonged. However, even when 
making the correct diagnosis the choice of drugs for 
treating CL is important as commonly used anti-
Ieishmanial drugs such as antimony medications 
are often not sufficient as single therapies. This may 
cause a prolonged course of disease and exposure to 
undesirable effects of antimony drugs and may be 
associated with disfiguring scars.
 The use of combination therapy using 
recommended doses of allopurinol and antimony 
drugs can shorten the duration of treatment. Prior 
to the described case, combination therapy for 
leishmaniasis in the model clinic had only been used 
in successful treatment of unresponsive cases of VL 
(20).
 The use of combination therapy to treat VL has 
been reported in several countries. Combination of 
allopurinol and low dose antimony drugs has been 
shown to be as effective as a high dose of the antimony 
drug alone or even more effective than single 
therapy (21,22)). There are other drugs in process of 
investigation, for example, oral miltefosine, amBisome, 
generic sodium stibogluconate, azithromycin, 
sitamaquine, artemisinin and fluconazole. There is 
evidence in literature that some topical applications 
such as 15% paromomycin plus 10% urea in white 
paraffin is effective when applied ≥ 4 weeks (23). 
 In the meantime, we suggest that following 
confirmed CL diagnosis the combination regime 
should be considered as first-line choice of therapy 
to prevent prolonged exposure to single antimony 
therapy which may lead to non-healing and resislilnt 
cases of CL. Although the report is limited to one 
case, it is possible to have these observations being 
transferable to similar populations and settings.
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